{"id":80550,"date":"2026-06-10T06:27:10","date_gmt":"2026-06-10T06:27:10","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/80550\/"},"modified":"2026-06-10T06:27:10","modified_gmt":"2026-06-10T06:27:10","slug":"assessing-novartis-swxnovn-valuation-after-a-strong-year-of-total-shareholder-returns","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/80550\/","title":{"rendered":"Assessing Novartis (SWX:NOVN) Valuation After A Strong Year Of Total Shareholder Returns"},"content":{"rendered":"\n

Find your next quality investment<\/a> with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.<\/p>\n

Why Novartis Stock Is On Investors\u2019 Radar Today <\/p>\n

Novartis (SWX:NOVN) is drawing fresh attention as investors reassess the stock after a solid year of total return and recent moves in the share price, prompting closer scrutiny of its fundamentals and valuation.<\/p>\n

See our latest analysis for Novartis.<\/a><\/p>\n

The recent share price around CHF118.38 comes after a 7 day share price return of 4.76% and a year to date share price return of 9.11%. The 1 year total shareholder return of 25.02% highlights stronger gains over time and suggests momentum has picked up recently compared with the weaker 90 day share price return, which was down 2.36%.<\/p>\n

If you are comparing Novartis with other opportunities in healthcare, this is a good moment to scan for companies applying AI in medicine and biotech using the 133 healthcare AI stocks<\/a><\/p>\n

With Novartis trading near CHF118 and a value score of 5, alongside an indicated intrinsic discount of about 61%, the key question now is simple: is this a genuine mispricing, or is the market already baking in future growth?<\/p>\n

Most Popular Narrative: 4.2% Undervalued <\/p>\n

Based on the most followed narrative, Novartis\u2019 fair value of CHF123.55 sits modestly above the last close at CHF118.38, framing the stock as slightly discounted.<\/p>\n

Novartis’ robust pipeline and rapid regulatory progress in advanced therapies (including biologics, gene, and cell therapies) positions the company to benefit from emerging healthcare technologies, potentially accelerating future earnings and margin growth as new high-value products launch.<\/p>\n

Read the complete narrative.<\/a><\/p>\n

Curious what kind of revenue profile and margin lift are baked into that view? The narrative leans on compounding top line growth, rising profitability and a future earnings multiple that assumes the market will still reward those trends.<\/p>\n

Result: Fair Value of CHF123.55 (UNDERVALUED)<\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a><\/p>\n

However, two pressure points could quickly challenge that fair value story: an earlier\u2011than\u2011expected loss of exclusivity on key drugs and tighter global pricing cuts that squeeze margins.<\/p>\n

Wall Street’s queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. \u2192 20 Compelling Space Companies<\/a> watchlist \u00b7 Global Space Race Investing Ideas<\/a> screener \u00b7 Scan the sector by valuation on Rocket Lab’s valuation page<\/a>.<\/p>\n

Next Steps <\/p>\n

With sentiment split between opportunity and caution, this is a good time to look at the data yourself and decide where you stand. You can start with the 4 key rewards and 1 important warning sign.<\/p>\n

Ready To Hunt For Your Next Idea? <\/p>\n

If you stop with just one stock, you risk missing others that might fit your goals even better. Put the data to work across a wider watchlist.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include NOVN.SW<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…\n","protected":false},"author":2,"featured_media":80551,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[1104,206,6614,842,1271],"class_list":["post-80550","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-fair-value","tag-novartis","tag-novartis-stock","tag-share-price","tag-total-shareholder-return"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116724396699857815","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/80550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=80550"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/80550\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/80551"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=80550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=80550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=80550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}